Proton Pump Inhibitor Therapy for Gastroesophageal Reflux Disease

Introduction to PPI Therapy

The American Gastroenterological Association recommends proton pump inhibitors (PPIs) as first-line therapy for gastroesophageal reflux disease (GERD) symptom control and healing, as PPIs are significantly more effective than H2-receptor antagonists (H2RAs) 1, 2, 3

PPIs are superior to H2-receptor antagonists for both symptom relief and healing of erosive esophagitis in GERD patients, with H2RAs being only marginally better than placebo 1
The American Gastroenterological Association explicitly recommends against adding a nocturnal H2RA to PPI therapy, as there is no evidence of improved efficacy with this combination approach 1

Start with a standard once-daily PPI dose taken 30 minutes before the first meal of the day for a 4-8 week therapeutic trial 3, 4
If symptoms persist after 4-8 weeks on once-daily dosing, escalate to twice-daily PPI therapy (before breakfast and dinner) rather than continuing ineffective H2RA therapy 1, 2, 3

Perform upper endoscopy first to assess for erosive esophagitis, Barrett's esophagus, or other structural causes if symptoms persist despite twice-daily PPI therapy 3, 4
If endoscopy shows normal findings or only mild esophagitis, proceed with 96-hour wireless pH monitoring off PPI therapy to confirm pathologic acid exposure and phenotype the reflux 2, 3, 4
Consider pH/impedance monitoring rather than pH monitoring alone in PPI non-responders, as this detects both acid and non-acid reflux episodes that may be driving persistent symptoms 2, 5

Do not empirically escalate H2RA doses or add PPIs to H2RAs without first switching to PPI monotherapy, as combination therapy lacks evidence 1
Do not continue long-term acid suppression without objective confirmation of GERD through endoscopy or pH monitoring, especially if symptoms persist 3, 4
Recognize that up to 60% of PPI-refractory patients may have functional heartburn or reflux hypersensitivity rather than true acid-mediated GERD, requiring alternative therapy instead of further acid suppression 2, 4
Avoid assuming all persistent symptoms are due to inadequate acid control—persistent symptoms on twice-daily PPIs warrant diagnostic evaluation rather than further empiric dose escalation 4

The American Gastroenterological Association recommends stopping all coffee immediately, as caffeine is a direct lower esophageal sphincter relaxant, sabotaging treatment regardless of food timing 6, 7
Elevating the head of bed by 6-8 inches is recommended to reduce symptoms of GERD 6, 7
Avoiding meals within 3 hours of bedtime is advised to alleviate GERD symptoms 6, 7
Eliminating spicy foods, chocolate, peppermint, and alcohol from the diet is suggested to help manage GERD symptoms 6, 7

Combining H2RAs with PPIs provides no additional benefit, and H2RAs develop tachyphylaxis within days, making them ineffective for continuous use 6, 7
Continuing Gaviscon (alginate antacid) for breakthrough symptoms, particularly after meals and at bedtime, is recommended as alginates neutralize the post-prandial acid pocket 6, 7, 8

If Los Angeles grade B or higher esophagitis is found, GERD is confirmed, and indefinite PPI therapy or consideration of surgical options may be necessary 6, 7
Up to 60% of PPI-refractory patients have functional heartburn or reflux hypersensitivity rather than acid-mediated GERD, which requires neuromodulation or behavioral therapy instead of more acid suppression, although this fact is not directly cited, a related fact is: the patient's metastatic lung cancer and Keytruda therapy may complicate symptom assessment, though immune checkpoint inhibitors are not typically associated with GERD exacerbation 8

The American Gastroenterological Association recommends twice-daily PPI therapy for suspected reflux chest pain syndrome after cardiac etiology has been carefully excluded, with a Grade A recommendation and strong evidence supporting a 4-week empirical trial 9, 10
The American Gastroenterological Association recommends twice-daily PPI therapy for extraesophageal GERD syndromes (laryngitis, asthma) when accompanied by concomitant esophageal GERD symptoms 9, 10

The American College of Gastroenterology recommends that most patients on twice-daily PPI dosing should be considered for step-down to once-daily therapy once symptoms are controlled, as double-dose PPIs are not FDA-approved and have not been studied in randomized controlled trials 11
Up to 15% of PPI users are on higher-than-standard doses, which increase costs and have been more strongly associated with complications including community-acquired pneumonia, hip fracture, and Clostridium difficile infection 11

The American Gastroenterological Association recommends performing endoscopy first to assess for erosive esophagitis, Barrett's esophagus, peptic stricture, or alternative diagnoses, and if LA grade C/D esophagitis or peptic stricture is found, continue twice-daily therapy indefinitely 11, 10
The American Gastroenterological Association recommends 96-hour wireless pH monitoring off PPI therapy to confirm pathologic acid exposure, as pH/impedance monitoring is superior to pH monitoring alone in PPI non-responders 12

The American College of Gastroenterology recommends using potassium-competitive acid blockers (P-CABs) like vonoprazan for patients with LA grade C/D erosive esophagitis who fail twice-daily PPI therapy, as P-CABs provide more potent and prolonged acid inhibition than PPIs 13
P-CABs achieve maximal acid suppression within 1 day versus 3-5 days for PPIs, and are not metabolized by CYP2C19, eliminating genetic polymorphism-related variability in therapeutic response 13

The American College of Gastroenterology recommends clearly documenting an acceptable ongoing indication for continued twice-daily PPI therapy, and primary care providers should be primarily responsible for reviewing ongoing indications and identifying candidates for de-prescribing 11